Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|May 6, 2015
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resectionM Schirripa, F Bergamo, C Cremolini, et al.
ESMO Open|March 6, 2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 studyB Borelli, E Fontana, M Giordano, et al.
ESMO Open|January 4, 2025
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI)M Reni, M Milella, F Bergamo, et al.
ESMO Open|September 2, 2025
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patientsA Pretta, V Nasca, F Marmorino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 7, 2018
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONOC Cremolini, C Antoniotti, S Lonardi, et al.
ESMO Open|January 28, 2025
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trialF Piscaglia, G Masi, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONOM M Germani, V Heinemann, D Rossini, et al.
ESMO Open|February 2, 2023
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI surveyM Reni, E Giommoni, F Bergamo, et al.
ESMO Open|June 25, 2026
Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 yearsA Pretta, G Rebecchi, G Maddalena, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2018
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONOE Dell'Aquila, C Cremolini, T Zeppola, et al.
Pageof 5